SCHEMBL968025

SCHEMBL968025

CCOC(=O)N1CCc2c(sc3nc(C)ncc23)C1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.58
RXFP1 Q9HBX9 3/20 0.58
ALDH1A1 P00352 6/20 0.50
PKM P14618 2/20 0.49
MAPT P10636 6/20 0.49
HTT P42858 3/20 0.49
LMNA P02545 2/20 0.49
GAA P10253 2/20 0.49
WEE1 P30291 1/20 0.46
ACACA Q13085 1/20 0.45
NPSR1 Q6W5P4 6/20 0.45
ADORA1 P30542 1/20 0.43
HPGD P15428 4/20 0.43
TSHR P16473 3/20 0.43
HSD17B10 Q99714 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
PDE4D Q08499 2/20 0.43
MAPK1 P28482 1/20 0.43
ADORA3 P0DMS8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL969134 0.84 KDM4E (0.58) KDM4ERXFP1ALDH1A1PKMMAPT
SCHEMBL968341 0.78 KDM4E (0.59) KDM4ERXFP1ALDH1A1PKMMAPT
SCHEMBL969839 0.77 KDM4E (0.58) KDM4ERXFP1ALDH1A1PKMMAPT
SCHEMBL967213 0.74 RXFP1 (0.66) KDM4ERXFP1ALDH1A1PKMMAPT
SCHEMBL969115 0.73 KDM4E (1.00) KDM4ERXFP1ALDH1A1PKMMAPT
SCHEMBL969761 0.73 RXFP1 (1.00) KDM4ERXFP1ALDH1A1PKMMAPT
SCHEMBL969428 0.73 HRH3 (0.35) KDM4ERXFP1ALDH1A1GAAHPGD
SCHEMBL73047 0.72 MAPT (0.48) KDM4ERXFP1ALDH1A1MAPTHTT
SCHEMBL966767 0.71 PARP1 (0.40) KDM4EALDH1A1MAPTHTTLMNA
SCHEMBL967160 0.70 PARP1 (0.40) KDM4EALDH1A1MAPTHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
EP-2162451-A2 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES Neurogen Corporation (US) 2010-03-17 EP disclosed
WO-2009003003-A2 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2008-12-31 WO disclosed
WO-2009003003-A2 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2008-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES HRH3, HRH4, HRH1 KDM4E 3037/4885RXFP1 581/4885ALDH1A1 812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.